IPO registrations (S-1, F-1) · Registrants
BIOVIE INC.
- SEC CIK
- 1580149 · filings on EDGAR ↗
- Former names
- NANOANTIBIOTICS, INC. (2013–2016)
- Registration
- Form S-1, first filed 2013-08-15, last 2026-08-14; 7 initial registrations, 25 amendments
- Outcome
- Final prospectus filed 2020-09-18; declared effective 2013-11-08; withdrawal requested 2019-07-01
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- NV
- Business address
- 680 W NYE LANE, SUITE 201, Carson City, NV 89703
- EIN
- 46-2510769
- Ticker
- BIVI, BIVIW (Nasdaq, Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- BIOVIE INC. on the corporate pages
On this site
- Federal award recipient: BIOVIE INC Fuzzy (name and state)
- Form D issuer: BIOVIE INC. EXACT (CIK (EXACT))
- SEC filer: BIOVIE INC. EXACT (CIK (EXACT))
- Person page: Cuong V Do Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
- Person page: R Richard Wieland Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 48
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-08-15 | S-1 | S-1 (registration) | NANOANTIBIOTICS, INC. | 0001548233-13-000011 ↗ |
| 2013-09-26 | S-1/A | S-1/A (amendment) | NANOANTIBIOTICS, INC. | 0001171520-13-000607 ↗ |
| 2013-10-15 | S-1/A | S-1/A (amendment) | NANOANTIBIOTICS, INC. | 0001548233-13-000014 ↗ |
| 2013-11-05 | S-1/A | S-1/A (amendment) | NANOANTIBIOTICS, INC. | 0001548233-13-000020 ↗ |
| 2013-11-08 | EFFECT | EFFECT (declared effective) | NANOANTIBIOTICS, INC. | 9999999995-13-003227 ↗ |
| 2017-01-19 | S-1 | S-1 (registration) | BIOVIE INC. | 0001520138-17-000021 ↗ |
| 2017-03-10 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-17-000096 ↗ |
| 2017-03-29 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-17-000109 ↗ |
| 2017-03-30 | EFFECT | EFFECT (declared effective) | BIOVIE INC. | 9999999995-17-000699 ↗ |
| 2019-04-23 | EFFECT | EFFECT (declared effective) | BIOVIE INC. | 9999999995-19-000794 ↗ |
| 2019-04-30 | S-1 | S-1 (registration) | BIOVIE INC. | 0001520138-19-000127 ↗ |
| 2019-06-28 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-19-000208 ↗ |
| 2019-07-01 | RW | RW (withdrawal request) | BIOVIE INC. | 0001520138-19-000215 ↗ |
| 2019-07-01 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-19-000217 ↗ |
| 2019-07-09 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-19-000233 ↗ |
| 2019-08-08 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-19-000268 ↗ |
| 2019-10-02 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-19-000360 ↗ |
| 2019-10-04 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-19-000374 ↗ |
| 2019-10-09 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-19-000382 ↗ |
| 2019-11-01 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-19-000418 ↗ |
| 2019-11-22 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-19-000485 ↗ |
| 2020-02-14 | RW | RW (withdrawal request) | BIOVIE INC. | 0001520138-20-000057 ↗ |
| 2020-03-11 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-20-000106 ↗ |
| 2020-07-15 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-20-000317 ↗ |
| 2020-08-21 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-20-000407 ↗ |
| 2020-09-08 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-20-000422 ↗ |
| 2020-09-17 | S-1MEF | S-1MEF (added securities) | BIOVIE INC. | 0001520138-20-000437 ↗ |
| 2020-09-17 | EFFECT | EFFECT (declared effective) | BIOVIE INC. | 9999999995-20-002475 ↗ |
| 2020-09-18 | 424B4 | 424B4 (final prospectus) | BIOVIE INC. | 0001520138-20-000439 ↗ |
| 2021-02-02 | EFFECT | EFFECT (declared effective) | BIOVIE INC. | 9999999995-21-000395 ↗ |
| 2022-11-10 | S-1 | S-1 (registration) | BIOVIE INC. | 0001520138-22-000512 ↗ |
| 2022-12-12 | RW | RW (withdrawal request) | BIOVIE INC. | 0001520138-22-000557 ↗ |
| 2023-04-10 | EFFECT | EFFECT (declared effective) | BIOVIE INC. | 9999999995-23-000882 ↗ |
| 2023-08-28 | EFFECT | EFFECT (declared effective) | BIOVIE INC. | 9999999995-23-002518 ↗ |
| 2024-11-21 | S-1 | S-1 (registration) | BIOVIE INC. | 0001520138-24-000429 ↗ |
| 2024-11-27 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-24-000434 ↗ |
| 2024-12-02 | EFFECT | EFFECT (declared effective) | BIOVIE INC. | 9999999995-24-003639 ↗ |
| 2025-07-03 | S-1 | S-1 (registration) | BIOVIE INC. | 0001520138-25-000198 ↗ |
| 2025-07-11 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-25-000205 ↗ |
| 2025-07-22 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-25-000216 ↗ |
| 2025-08-04 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-25-000235 ↗ |
| 2025-08-07 | EFFECT | EFFECT (declared effective) | BIOVIE INC. | 9999999995-25-002514 ↗ |
| 2025-11-18 | EFFECT | EFFECT (declared effective) | BIOVIE INC. | 9999999995-25-003311 ↗ |
| 2026-06-29 | EFFECT | EFFECT (declared effective) | BIOVIE INC. | 9999999995-26-002154 ↗ |
| 2026-07-17 | S-1 | S-1 (registration) | BIOVIE INC. | 0001520138-26-000276 ↗ |
| 2026-07-31 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-26-000299 ↗ |
| 2026-08-06 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-26-000313 ↗ |
| 2026-08-14 | S-1/A | S-1/A (amendment) | BIOVIE INC. | 0001520138-26-000350 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Sherman Michael Edward | Director | 11 | 2018–2026 | ||
| Adams Jonathan M | Director,Officer; Officer | chief operating officer; Chief Operating Officer; EVP Liver Cirrhosis Programs | 8 | 2018–2022 | |
| Anderson Julie G | Director | 3 | 2018–2020 | ||
| Do Cuong V | Director; Director,Officer | CEO & President; President & CEO | 20 | 2018–2026 | person page Fuzzy |
| Sooch Mina | Director | 4 | 2018–2020 | ||
| Lang James Paul | Director | 11 | 2018–2026 | ||
| WIELAND R RICHARD | Director; Officer | interim CFO | 3 | 2018–2020 | person page Fuzzy |
| Kumar Hari | Director | 4 | 2019–2020 | ||
| Yeramian Patrick D | Officer | Chief Medical Officer | 2 | 2019–2020 | |
| MARKHAM PENELOPE | Officer | Chief Science Officer; EVP Liver Cirrhosis R&D | 5 | 2019–2023 | |
| KIM JOANNE WENDY | Officer | CFO; Chief Financial officer; Chief Financial Officer | 13 | 2019–2026 | |
| GORLIN STEVE | Director | 13 | 2020–2023 | ||
| ROGICH SIGMUND | Director | 7 | 2020–2026 | ||
| Ahlem Clarence N. | Officer | EVP Neuroscience Product Dev.; EVP of Product Development | 4 | 2021–2023 | |
| BERMAN RICHARD J | Director | 9 | 2021–2025 | ||
| Hariri Robert J | Director | 6 | 2021–2025 | ||
| READING CHRISTOPHER | Officer | EVP Neuroscience R&D | 4 | 2021–2023 | |
| Palumbo Joseph M | Officer; Other | Chief Medical Officer | 9 | 2021–2026 | |
| PEIZER TERREN S | Director,TenPercentOwner | 4 | 2022–2023 | ||
| Chappell Amy Suzon | Director | 3 | 2025–2026 | ||
| Farag Kameel D. | Director | 2 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2022-07-25 | BIOVIE INC. | Biotechnology | $6,000,000 | $6,000,000 | 1 | 1 |
| 2018-07-10 | BIOVIE INC. | Biotechnology | $6,200,000 | $3,200,000 | 5 | 1 |
| 2017-05-09 | BIOVIE INC. | Biotechnology | $600,000 | $0 | 0 | 1 |
| 2017-01-19 | BIOVIE INC. | Biotechnology | Indefinite | $200,000 | 1 | 1 |
| 2016-10-26 | BIOVIE INC. | Biotechnology | $500,000 | $10,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.